Literature DB >> 30165348

Inhibition of Proteasomal Deubiquitinase by Silver Complex Induces Apoptosis in Non-Small Cell Lung Cancer Cells.

Xin Chen1, Qianqian Yang1, Jinghong Chen1,2, Peiquan Zhang1, Qingtian Huang1, Xiaolan Zhang1, Li Yang1, Dacai Xu1, Chong Zhao1,3, Xuejun Wang1,4, Jinbao Liu1.   

Abstract

BACKGROUND/AIMS: The ubiquitin proteasome system (UPS) is responsible for the degradation of most intracellular proteins, and proteasomal deubiquitinases (DUBs) have recently been highlighted as novel anticancer targets. It is well documented that copper complexes can inhibit UPS function through targeting both 20S proteasome and proteasomal DUBs. The antineoplastic activities of silver complexes have received much attention, but the exact mechanisms are not fully elucidated. In this study, we aim to investigate the effects of a novel silver complex [Ag(S2CN(C2H5)2)]6 (AgDT) on UPS function and its anticancer potential in non-small cell lung cancer (NSCLC).
METHODS: Cell viability assay (i.e., the MTS assay) and flow cytometry assay were used to analyze the cell viability and apoptosis. Proteasome inhibition was measured using 20S proteasome activity assay and 19S proteasomal DUBs activity assay. Western blot analysis and immunohistochemistry were performed to detect protein levels. The in vivo antitumor activity of AgDT was assessed with nude xenografts.
RESULTS: Silver ions, alone or in combination with disulfiram (DSF), induced UPS inhibition in NSCLC cells mainly through inhibition of proteasomal DUBs activities. Silver complex AgDT triggered intracellular accumulation of ubiquitinated proteins, and prevented the degradation of surrogate substrate GFPu. Mechanistically, AgDT potently inhibited the activities of proteasomal DUBs USP14 and UCHL5, without altering the 20S proteasome peptidases. Moreover, AgDT induced apoptosis in NSCLC cells and significantly inhibited tumor growth in xenografts.
CONCLUSION: Our findings suggest that silver complex AgDT is a novel metal-based proteasomal DUBs inhibitor, and pharmacologic inhibition of USP14 and UCHL5 could prove to be an effective therapeutic strategy for NSCLC.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Apoptosis; Deubiquitinases; Lung cancer; Proteasome; Silver complex

Mesh:

Substances:

Year:  2018        PMID: 30165348     DOI: 10.1159/000493041

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  5 in total

1.  Metalo components exhibiting significant anticancer and antibacterial properties: a novel sandwich-type like polymeric structure.

Authors:  Ahmet Karadağ; Nesrin Korkmaz; Ali Aydın; Hüseyin Akbaş; Şaban Tekin; Yusuf Yerli; Fatih Şen
Journal:  Sci Rep       Date:  2020-07-27       Impact factor: 4.379

2.  Ubiquitin-specific peptidase 28 enhances STAT3 signaling and promotes cell growth in non-small-cell lung cancer.

Authors:  Pengling Li; Ziming Huang; Jipeng Wang; Wei Chen; Jianan Huang
Journal:  Onco Targets Ther       Date:  2019-02-26       Impact factor: 4.147

3.  USF1-ATRAP-PBX3 Axis Promote Breast Cancer Glycolysis and Malignant Phenotype by Activating AKT/mTOR Signaling.

Authors:  Dandan Wang; Xiaoying Jin; Mengxia Lei; Ying Jiang; Yali Liu; Fei Yu; Yan Guo; Bing Han; Yue Yang; Weiling Sun; Ying Liu; Guangchun Zeng; Feng Liu; Jing Hu; Xuesong Chen
Journal:  Int J Biol Sci       Date:  2022-03-14       Impact factor: 6.580

Review 4.  Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

Authors:  Huanjie Yang; Xin Chen; Kai Li; Hassan Cheaito; Qianqian Yang; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Semin Cancer Biol       Date:  2019-12-26       Impact factor: 15.707

5.  The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study.

Authors:  Kuan-Lin Kuo; Shing-Hwa Liu; Wei-Chou Lin; Po-Ming Chow; Yu-Wei Chang; Shao-Ping Yang; Chung-Sheng Shi; Chen-Hsun Hsu; Shih-Ming Liao; Hong-Chiang Chang; Kuo-How Huang
Journal:  Cells       Date:  2019-10-17       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.